Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucopyranosyl lipid adjuvant-aqueous formulation
- Development stage
- Phase 1
- Lead developer
- Access to Advanced Health Institute
- Modality
- Small Molecules
- Administration
- Intradermal, Mucosal
01
Overview
GLA-AF (glucopyranosyl lipid adjuvant-aqueous formulation) is a synthetic vaccine adjuvant designed to enhance immune responses to vaccines, particularly for intradermal and mucosal administration. It is an emulsion-free aqueous formulation of the synthetic Toll-like receptor 4 (TLR4) agonist known as glucopyranosyl lipid adjuvant (GLA). GLA-AF has been shown in preclinical and clinical studies to safely boost both humoral and cellular immune responses when co-administered with various antigens, including influenza and HIV vaccine candidates. Its mechanism of action involves activation of TLR4 on antigen-presenting cells, leading to enhanced Th1-type immunity and increased antibody titers. The development of GLA-AF addresses the need for potent, safe intradermal or mucosal vaccine adjuvants that can be self-administered or used in pandemic scenarios[1][2][8].
- Other names
- glucopyranosyl lipid adjuvant-aqueous formulationGLA-AF
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on glucopyranosyl lipid adjuvant-aqueous formulation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glucopyranosyl lipid adjuvant-aqueous formulation.